KeisukeShiraiMD

Oncology • Lebanon, NH

Head & Neck Cancer, Hospice & Palliative, Melanoma, Thoracic Cancer

Professor, Medicine, Dartmouth Cancer Center, Dartmouth Hitchcock Medical Center

Join to view full profile

Dr. Shirai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shirai's full profile

Already have an account?

Office
1 Medical Center Dr
# Dhmc
Lebanon, NH 03756
Phone+1 603-650-7854

Education & Training

Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 2005 - 2008
UPMC Medical EducationResidency, Internal Medicine, 2002 - 2005
Faculty of Medicine Kyoto UniversityClass of 1997

Certifications & Licensure

VT State Medical License 2023 - 2026
NH State Medical License 2015 - 2025
SC State Medical License 2005 - 2017
PA State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer Start of enrollment: 2007 Jun 04
Completed
Phase 2
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers Start of enrollment: 2009 Nov 01
Completed
Phase 1
Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2009 Dec 16
Completed
Phase 1
A Study in Advanced Solid Tumors Start of enrollment: 2010 Jun 01
Completed
Phase 2
Everolimus Versus Placebo in Head and Neck Cancer Start of enrollment: 2010 Apr 01
Terminated
Phase 2
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12
Terminated
Phase 1, Phase 2
Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells Start of enrollment: 2012 Oct 01
Terminated
Phase 1
Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer Start of enrollment: 2013 Mar 01
Completed
Phase 1
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Docetaxel and Lycopene in Metastatic Prostate Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 1
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma Start of enrollment: 2015 Oct 01
Active, not recruiting
Phase 1, Phase 2
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer Start of enrollment: 2019 Nov 05
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.
Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, Jesús Antonio Ocejo Gallegos, Jabra Zarka
The British Journal of Dermatology. 2025-01-24
Methylation cytometric pretreatment blood immune profiles with tumor mutation burden as prognostic indicators for survival outcomes in head and neck cancer patients on...
Ze Zhang, Kartik Sehgal, Keisuke Shirai, Rondi A Butler, John K Wiencke
NPJ Precision Oncology. 2024-11-18
1 citations
Depletion of conventional CD4T cells is required for robust priming and dissemination of tumor antigen-specific CD8T cells in the setting of anti-CD4 therapy.
Delaney E Ramirez, Christo P C Dragnev, Tyler G Searles, Nathaniel Spicer, Tiffany Chen
Journal for Immunotherapy of Cancer. 2024-11-09

Press Mentions

Resident and Circulating Memory T Cells Persist for Years in Melanoma Patients with Durable Responses to ImmunotherapyMarch 24th, 2021
At the Hospitals: Aug. 18, 2019August 17th, 2019
Dartmouth-Hitchcock Health Funds $1M Annually for Dedicated Cancer Clinician Research TimeJuly 31st, 2019